SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of preclinical data demonstrating the potential of infigratinib for treating FGFR-driven cancers derived from multiple tissue types. The data was presented during the AACR 2019 Annual Meeting in a poster entitled "Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors."
"Recent data shows that fusion proteins involving FGFR have been identified in a diverse range of solid tumors including lung, breast, thyroid and prostate cancers, as well as cholangiocarcinoma and bladder cancer," said Sameek Roychowdhury, M.D., Ph.D., associate professor of medical oncology at The Ohio State University. "Given the fact that scientists are identifying more tumor types driven by mutations in FGFRs, it expands the potential for a compound like infigratinib as an effective treatment for many more cancers than previously understood."
Researchers identified FGFR fusion positive patient samples and developed patient-derived xenograft (PDX) models to ascertain the effect of infigratinib treatment. Specifically, they studied PDX models of cholangiocarcinoma, breast cancer, liver cancer, gastric cancer and glioma, determining that treatment with infigratinib resulted in a reduction in tumor volume in all samples compared to inactive treatment. In addition, the research details the identification and characterization of a novel FGFR fusion in prostate cancer.
"While previously presented data have shown the promise of infigratinib for the treatment of cholangiocarcinoma and urothelial carcinoma, this data provides a clear rationale for performing tumor-agnostic clinical trials across all molecularly defined solid tumors," said Gary Li, PhD, senior vice president of translational medicine at QED Therapeutics. "We will support the prompt initiation of these trials in the hopes of developing an important treatment for patients with serious and life-threatening cancers such as bile duct, brain, bladder, lung, breast, thyroid and prostate cancer."
The full poster can be viewed at www.qedtx.com/AACR2019/
About QED Therapeutics
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven diseases. Our lead investigational candidate is infigratinib (BGJ398), an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown meaningful clinical activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia and other skeletal dysplasias. We plan to conduct further clinical trials to evaluate the potential for infigratinib to treat patients with other FGFR-driven tumor types and rare disorders.
For more information on QED Therapeutics, please visit the company's website at www.qedtx.com
This press release contains forward-looking statements. All statements contained herein other than statements of historical fact constitute forward-looking statements, including statements relating to expectations, plans, and prospects regarding QED Therapeutics' clinical development plans, clinical trial results, timing and completion of clinical trials and clinical and therapeutic potential of infigratinib. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to, QED Therapeutics' ability to initiate and continue its planned clinical trials of infigratinib and to advance infigratinib in clinical development. Moreover, QED Therapeutics operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of QED Therapeutics' management as of the date of this release and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements in this press release are based on information available to QED Therapeutics as of the date hereof, and QED Therapeutics disclaims any obligation to update these forward-looking statements.
SOURCE QED Therapeutics